Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming David Cullinane .
Filed returns
15
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 19 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Access to an antiviral medication for the treatment of COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2024 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 17 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Health | Pfizer COVID-19 anti-viral treatment (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2022 | Pfizer | Economic Development and Industry | Proposed COVID-19 Trips waiver (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2021 | Pfizer | Health | Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) | 5 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Pfizer | Health | Outline Ireland's medicine reimbursement system and timelines compared with other countries (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Highlight Ireland's slowness in reimbursing new medicines for Irish patients compared with other EU countries (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Taxation | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 21 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 12 | 80.0% | |
| Economic Development and Industry | 2 | 13.3% | |
| Taxation | 1 | 6.7% |